Research progress of personalized medicine for immune checkpoint blockades

Abstract

Abstract:

Immune checkpoint blockades, which release the brake of immune system to enhance anti-cancer immune response, stand out in the cancer immunotherapy field due to their remarkable and long-lasting effect. However, the overall response rate for currently proved immune checkpoint inhibitors is only about 10%-40%. How to predict patients' outcome of these drugs has becoming the crucial focus in clinical. Three major components considered as the key to describe the cancer-immune interaction in immune checkpoint therapy will be discussed in this review.

Key words: immunotherapy, immune checkpoint blockades, personalized medicine, PD-1/PD-L1 inhibitors

CLC Number:

R969.1

WANG Weili，LIAO Ping, XU Biaobo，ZHOU Chengfang, XIE Shangchen, SHEN Dongya, HE Yijing, Howard L. Mcleod. Research progress of personalized medicine for immune checkpoint blockades[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 228-232.

References

［1］Sharma P, Allison JP. The future of immune checkpoint therapy［J］. Science, 2015,6230(348):56-61.
［2］Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial［J］. Lancet,2016,387(10031):1909-1920.
［3］Ito A, Kondo S, Tada K, et al. Clinical Development of Immune Checkpoint Inhibitors［J］. Biomed Res Int,2015,2015:1-12.
［4］Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation［J］. New Engl J Med,2011,364(26):2507-2516.
［5］Kumarakulasinghe NB, van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)［J］. Respirology,2015,20(3):370-378.
［6］Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway［J］. New Engl J Med,2016,375(18):1767-1778.
［7］Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer［J］. New Engl J Med,2012,366(26):2443-2454.
［8］Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］. Clin Cancer Res, 2014, 20(19):5064-5074.
［9］Kaufman HL. Precision immunology: the promise of immunotherapy for the treatment of cancer［J］. J Clinical Oncol,2015,33(12):1315-1317.
［10］Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer［J］. Nature, 2013,500(7463):415-421.
［11］Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］. Science, 2015,348(6230):124-128.
［12］Scarpa M, Ruffolo C, Canal F, et al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance［J］. Oncotarget,2015,6(41):43472-43482.
［13］Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer［J］. Curr Treat Option On,2015,16(7):30.
［14］Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency［J］. New Engl J Med,2015,372(26):2509-2520.
［15］Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma［J］. Brit J Dermatol,2016,174(1):146-151.
［16］Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients［J］. Brit J Cancer,2015,112(12):1904-1910.
［17］Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival［J］. Ann Oncol,2013,24(6):1697-1703.
［18］Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab［J］. Clin Cancer Res,2015,21(24):5453-5459.
［19］Schumacher TN, Schreiber RD. T cell exclusion, immune privilege, and the tumor microenvironment［J］. Science,2015, 348(6230):69-74.
［20］Wang W, Yu D, Sarnaik AA,et al. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment［J］. Ann Dermatol Venereol,2012,140(6/7):448-451.
［21］Deschoolmeester V, Baay M, Van Marck E, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients［J］. BMC immunol,2010,11(1):19.
［22］Berghoff AS, Ricken G, Widhalm G, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases［J］. Histopathology,2015,66(2):289-299.
［23］Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory［J］. J Clin Oncol,2011,29(6):601-603.
［24］Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer［J］. Science,2015,348(6230):62-68.
［25］Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force［J］. J Transl Med, 2012,10:205.
［26］Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction［J］. J Clin Oncol,2011,29(6):610-618.
［27］Feng Z, Puri S, Moudgil T, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma［J］. J Immunother Cancer,2015, 3:47.
［28］Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma［J］. Cancer Immunol Immunother,2014,63(5):449-458.
［29］Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes［J］. Cancer Res,2012,72(11):2746-2756.
［30］Fischer K, Hoffmann P, Voelkl S,et al.Inhibitory effect of tumor cell-derived lactic acid on human T cells［J］. Blood,109(9):3812-3819.
［31］Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet?［J］. Science,2013,339(6117):286-291.
［32］Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis［J］. Nature,2015,522(7556):345-348.
［33］Zelenay S, van der Veen AG, Bottcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity［J］. Cell,2015, 162(6):1257-1270.
［34］Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy［J］. Cancer J, 2010,16(4):399-403.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[4]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[5]	SUN Yuanyuan, DENG Kunhong, WANG Siyi, KUANG Yun, ZOU Chan, GUO Chengxian, HE Qingnan, LIU Helin, YANG Guoping. Design and implementation of electronic identity application for gene-directed personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 274-280.
[6]	LI Wei, HU Jiali, WANG Kai, HE Yijing. Research progress and prospect of immunotherapy in the treatment of melanoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
[7]	MIN Hang, GUO Mengran, YE Yue, XU Xiaoshuang, ZHEN Donghu. Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 223-229.
[8]	ZHAO Quanming, YANG Yang. Progress in drug therapy for advanced triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
[9]	CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.
[10]	ZHANG Kaiting, CHEN Naihan. Development of therapeutic biologics in cancer treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 32-43.
[11]	ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.
[12]	LV Pei-yu, YUAN Hong, ZHOU Hong-hao, OUYANG Dong-sheng. Genetic variation of cytochrome P450 oxidase and personalized medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1281-1287.
[13]	LUO Zhi-ying, ZHANG Wei. The educational strategies for pharmacogenomics Translational Medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 588-592.
[14]	CHEN Cun-guo, LI Shao-bo, WANG Xin-xin, JIN Xiao-hong, TONG Xia-sheng, LAI Xiao-ying. Effects of specific immunotherapy on IL-10 and CD₄⁺CD₂₅⁺ regulatory T cells in asthmatic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 871-875.
[15]	LI Shao-bo, JIN Xiao-hong, WANG Xin-xin, LAI Xiao-ying, TONG Xia-sheng. Effect of specific immunotherapy on TGF-β₁/ Smads in asthmatic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(11): 1229-1233.